Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.360
+0.010 (0.43%)
Oct 19, 2026, 11:11 AM EDT - Market open
Editas Medicine Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 47.01 | 40.52 | 32.31 | 78.12 | 19.71 | 25.54 | |
Revenue Growth | 20.83% | 25.39% | -58.64% | 296.32% | -22.83% | -71.85% |
Cost of Revenue | 84.96 | 89.95 | 199.25 | 177.65 | 174.96 | 142.51 |
Gross Profit | -37.95 | -49.43 | -166.93 | -99.53 | -155.25 | -116.96 |
Selling, General & Admin | 45.51 | 49.9 | 71.99 | 69.65 | 70.7 | 76.18 |
Operating Expenses | 45.51 | 49.9 | 71.99 | 69.65 | 70.7 | 76.18 |
Operating Income | -83.46 | -99.34 | -238.92 | -169.18 | -225.95 | -193.15 |
Interest Expense | -4.07 | -6.17 | -2.19 | - | - | - |
Interest & Investment Income | 6.08 | 8.31 | 16.25 | 17.57 | 5.52 | 0.61 |
Other Non Operating Income (Expenses) | 2.79 | - | - | - | - | 0.04 |
EBT Excluding Unusual Items | -78.66 | -97.2 | -224.86 | -151.62 | -220.43 | -192.5 |
Merger & Restructuring Charges | 7.63 | -56.92 | -12.23 | - | - | - |
Gain (Loss) on Sale of Investments | -2.89 | -2.19 | -0 | -1.6 | - | - |
Gain (Loss) on Sale of Assets | -0.03 | -3.76 | - | - | - | - |
Pretax Income | -73.95 | -160.06 | -237.09 | -153.22 | -220.43 | -192.5 |
Net Income | -73.95 | -160.06 | -237.09 | -153.22 | -220.43 | -192.5 |
Net Income to Common | -73.95 | -160.06 | -237.09 | -153.22 | -220.43 | -192.5 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 101 | 89 | 82 | 76 | 69 | 68 |
Shares Outstanding (Diluted) | 101 | 89 | 82 | 76 | 69 | 68 |
Shares Change | 21.72% | 7.78% | 8.39% | 10.63% | 1.55% | 15.37% |
EPS (Basic) | -0.73 | -1.80 | -2.88 | -2.02 | -3.21 | -2.85 |
EPS (Diluted) | -0.73 | -1.80 | -2.88 | -2.02 | -3.21 | -2.85 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -120.55 | -165.85 | -219.11 | -136.9 | -181.47 | -171.78 |
Free Cash Flow Per Share | -1.19 | -1.87 | -2.66 | -1.80 | -2.64 | -2.54 |
Gross Margin | -80.75% | -122.00% | - | -127.40% | - | - |
Operating Margin | -177.56% | -245.15% | -739.37% | -216.56% | -1146.26% | -756.13% |
Profit Margin | -157.32% | -395.01% | -733.72% | -196.13% | -1118.26% | -753.61% |
Free Cash Flow Margin | -256.46% | -409.30% | -678.06% | -175.23% | -920.59% | -672.49% |
EBITDA | -81.04 | -94.06 | -233.11 | -163.12 | -219.61 | -188.09 |
EBITDA Margin | -172.40% | -232.13% | - | -208.80% | - | - |
D&A For EBITDA | 2.43 | 5.28 | 5.81 | 6.06 | 6.34 | 5.05 |
EBIT | -83.46 | -99.34 | -238.92 | -169.18 | -225.95 | -193.15 |
EBIT Margin | -177.56% | -245.15% | - | -216.56% | - | - |